reports
ImmuCell Announces Unaudited Financial Results for the Quarter Ended M...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025 PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2025. Product Sales Highlights: Product sales during the first quarter of 2025 increased by 11% to approximately $8.1 millio...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025 Conference Call Scheduled for Thursday, May 15, 2025 at 9:00 AM ET PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025. The...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025 PORTLAND, Maine, April 08, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2025. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the clos...
ImmuCell Hires Chief Financial Officer
ImmuCell Hires Chief Financial Officer PORTLAND, Maine, April 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has hired Timothy C. Fiori to serve as its Chief Financial Officer. Mr. Fiori brings to ImmuCell approximately 24 years of finance and commercial operating experience with IDEXX Laboratories in Westbrook, Maine. He is a 2001 gra...
ImmuCell Announces Initiation of Investigational Product Use of Re-Tai...
ImmuCell Announces Initiation of Investigational Product Use of Re-Tain® PORTLAND, Maine, April 02, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it is initiating Investigational Product use of Re-Tain®. The Company intends to use this opportunity to test market acceptance of the product through a controlled launch. This initiative also help...
ImmuCell Announces Unaudited Financial Results for the Quarter and Yea...
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024 PORTLAND, Maine, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2024. Product Sales Highlights: Fourth quarter of 2024 product sales increased 52% to approximately $7....
ImmuCell to Announce Unaudited Financial Results for the Quarter and Y...
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024 Conference Call Scheduled for Wednesday, February 26, 2025 at 9:00 AM ET PORTLAND, Maine, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter and year ended December 31, 2024 after the market closes o...
ImmuCell Announces Settlement of Insurance Claim Related to Previously...
ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses PORTLAND, Maine, Jan. 16, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has settled an insurance claim covering some of the losses incurred from production contamination events. The Company settled a long outstanding insurance ...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Ful...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024 PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter and full year ended December 31, 2024. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaud...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended S...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024 PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2024. Q3 2024 Highlights: Product sales increased 11% over the comparable quarter in 2023.Product sales increased 51% o...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024 Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ET PORTLAND, Maine, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2024 after the market closes on Wednesday, Nove...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024 PORTLAND, Maine, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024. Preliminary, Unaudited Total Sales Results: 20242023$ Increase % IncreaseDuring the Three-Month Periods Ended...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended J...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024 PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2024. Q2 2024 Highlights: Product sales increased 55% versus the comparable quarter in 2023.Product sales increased 82% versus th...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024 Conference Call Scheduled for Wednesday, August 14, 2024 at 9:00 AM ET PORTLAND, Maine, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2024 after the market closes on Tuesday, August 13, 2024. ...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024 PORTLAND, Maine, July 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2024, which ended June 30, 2024. Preliminary, Unaudited Total Sales Results: 2024 2023 $ Increase % Increase During the Three-Month Per...
ImmuCell Provides Update on Regulatory Status of Product Development I...
ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain® PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today provided a regulatory update on the status of its product development initiative for Re-Tain®. As previously disclosed, the Company recently received a Technical Section Incomplete Letter (Inc...
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders PORTLAND, Maine, June 04, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) will be conducted virtually on Thursday, June 13, 2024, at 9:30 AM ET, as previously disclosed in its Proxy Statement filed with the Securities and ...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended M...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024 PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2024. Management’s Discussion:“Our preliminary, unaudited product sales for the first quarter of 2024 were first reported on Ap...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024 Conference Call Scheduled for Wednesday, May 15, 2024 at 9:00 AM ET PORTLAND, Maine, May 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2024 after the market closes on Tuesday, May 14, 2024. The ...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 PORTLAND, Maine, April 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024. Preliminary, Unaudited Total Sales Results: 20242023$ Increase % IncreaseDuring the Three-Month Periods Ended Ma...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.